our Premium Content: News alerts, weekly reports and conference planners

DRUG:

RD133

News alerts, weekly reports and conference planners

Company:

IASO BIO

Drug class:

CD19-targeted CAR-T immunotherapy, Mesothelin-targeted CAR-T immunotherapy

Related drugs:

‹

YTS105 (0)

anti- MESO CAR-T cells (0)

anti-mesothelin CAR T cells (0)

iCasp9M28z T cell infusion (0)

meso-CART (0)

mesothelin-targeted CAR-T immunotherapy (0)

axicabtagene ciloleucel (24)

lisocabtagene maraleucel (23)

tisagenlecleucel-T (15)

brexucabtagene autoleucel (4)

CB-010 (2)

CTX110 (2)

relmacabtagene autoleucel (2)

CAR-T19/CAR-T22 immunotherapy (1)

Anti-CD19/CD20/CD22 CAR T-Cells (0)

Autologous CAR-T cells (0)

CAR-20/19-T Cells (0)

CAR-T CD19/CD20/CD22/CD30 (0)

CAR19T2 T cells (0)

CAR20.19.22 T (0)

CARCIK-CD19 (0)

CART-138/BCMA/19/more (0)

CD19 and CD22 targeted prime CAR-T (0)

CD19 specific CAR T cell therapy (0)

CD19 targeted CAR-T (0)

CD19-7×19 CAR-T (0)

CD19-CAR-DNT (0)

CD19-CAR-T2 cells (0)

CD19-CAR.CD45RA- negative T-cells (0)

CD19-CAR_Lenti T cells (0)

CD19-CD22 CAR-T (0)

CD19-CD34 CAR transduced T cells (0)

CD19-CD34t metabolically programmed CAR transduced T-cells (0)

CD19-PD1-CART cell (0)

CD19-targeted CAR-T cells (0)

CD19.CAR-T (0)

CD19/BAFF-R dual CAR T (0)

CD19/BCMA targeted CAR T-cells (0)

CD19/CD20 CAR T-cells (0)

CD19/CD22 CAR T-cells (0)

CD19/CD22 CAR-T cell therapy (0)

CD19/CD22 chimeric antigen receptor T cell (0)

CD19/CD22 dual-target CAR-T (0)

CD19CAR/virus specific T cell therapy (0)

CD19x22 CAR T (0)

CD20-CD19 cCAR T cells (0)

CD22/CD19 CAR T (0)

CLBR001/SWI019 (0)

CLIC-1901 (0)

CMV/CD19 bi-Specific CAR T (0)

DDCAR-CD19 T-cells (0)

EGFRt/19-28z/4-1BBL CAR T cells (0)

RPM CD19-mbIL15-CAR-T cells (0)

STK-009/SYNCAR-001 (0)

UCD19 CAR T Cells (0)

UF-KURE19 (0)

WZTL-002 (0)

XYF19 CAR-T cells (0)

YTS101 (0)

inaticabtagene autoleucel (0)

alloCART-19 cell therapy (0)

CRC01 (0)

anti-CD19 CAR-T cell therapy (0)

anti-CD19 CAR-T therapy (0)

anti-CD19 DASH CAR-T (0)

anti-CD19-CAR (0)

anti-CD19-CAR γδT (0)

anti-CD19/CD22 CAR-T cells (0)

autologous 3rd generation CD19-targeting CAR T cell therapy (0)

autologous TriCAR T (0)

human derived (0)

huCART19 (0)

huCART19-IL18 (0)

human anti CD19 CAR-T cells (0)

humanized CD19 CAR-T cell therapy (0)

humanized CD19 CAR-T cells (0)

iC9-CAR19 cells (0)

multi-CAR-T cell therapy (0)

multi-target gene-modified CAR-T/TCR-T cell immunotherapy (0)

murine CD19 CAR-T cell therapy (0)

murine autologous anti-CD19 CART cells (0)

YTB323 (0)

sequential different B cell antigen-targeted CAR T-cell therapy (0)

JCAR015 (0)

MB-CART2019.1 (0)

MSLN-CAR-T cell therapy (3)

CD40 ligand expressing MSLN-CAR T (0)

GC008t (0)

GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)

anti- MESO CAR-T cells (0)

anti-mesothelin CAR T cells (0)

iCasp9M28z T cell infusion (0)

meso-CART (0)

mesothelin-targeted CAR-T immunotherapy (0)

›

2years

Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors (clinicaltrials.gov)

P1, N=24, Recruiting, Tongji Hospital | Not yet recruiting --> Recruiting

2 years ago

Enrollment open

MSLN (Mesothelin)

MSLN positive

RD133

over2years

An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors (clinicaltrials.gov)

P1, N=24, Recruiting, The First Affiliated Hospital with Nanjing Medical University

over 2 years ago

Clinical • New P1 trial

MSLN (Mesothelin)

MSLN positive

RD133

over2years

Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors (clinicaltrials.gov)

P1, N=24, Not yet recruiting, Tongji Hospital

over 2 years ago

Clinical • New P1 trial

MSLN (Mesothelin)

MSLN positive

RD133